- Biotech company Destiny Pharma revealed positive results from its second Phase 1 safety clinical study evaluating its anti-microbial nasal gel's potential to cause irritation when administered topically.

The study, required under the Investigational New Drug application opened in February 2018, achieved the primary objective of a low cumulative irritancy score for both concentrations with 'high statistical significance when compared to a placebo of distilled water,' the company said.

'These positive results also support the advancement of XF-73 in Destiny Pharma's Phase 1 dermal infection programme and reinforce the target product profile of XF-73 for both indications.  XF-73 nasal gel is planned to move into Phase 2b clinical trials under the US Food and Drug Administration (FDA) Qualified Infectious Disease Product (QIDP) and Fast Track designation,' said Neil Clark, Chief Executive of Destiny Pharma.

'This study will examine the nasal antibacterial activity and safety of the 0.2% w/w XF-73 nasal gel in over 150 patients at risk of post-surgical infections. The study design is under review at the FDA and it is planned to report data towards the end of 2019.'

At 8:37am: [LON:DEST] Destiny Pharma Plc share price was +1p at 75p

Story provided by